GREY:ICOTF - Post by User
Post by
DrHolidayon Jul 09, 2018 2:04pm
131 Views
Post# 28288814
WuXi market cap of USD $99 billion
WuXi market cap of USD $99 billionNice to see IMNP partnering with WuXi Biologics, which currently has a
market cap of $99 billion USD.
WuXi knows that ICO has the licensing rights to Bertilimumab, and this makes ICO attractive as a potential takeover once IMNP successfully passes phase 2 and 3 trials. So, it is now not just AstraZeneca or Gilead, but WuXi too who are big pharma companies looking for an acquisition.
Wuxi is interested in IMNP because of Bertilimumab, and AstraZeneca and Gilead are interested in ICO because of Oral B Amphotericin. Both are multi billion dollar drug markets.
So, ICO is an attractive dance partner for both of these drugs in the product pipeline.
If WuXi were to acquire IMNP and ICO, then they wouldn`t have to pay the USD $32 million in milestone payments as per the agreement terms.
32 million is worth about 52 cents for each share of ICO based upon 84 million outstanding.
This 52 cents place no value on Oral B Amphotericin and no value on the intellectual property rights of ICO either. The 1.50 to 3.00 target by Doublebank is quite conservative in my opinion.
DOC.